Please assess the completion status of the following clinical trial:

Trial Title: Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with metastatic castrate-resistant prostate cancer (prostate cancer progressing despite castrate levels of testosterone \<50 ng/dL), using standard measures of progression defined by PCWG2~2. Have received at least 4 cycles of docetaxel or cabazitaxel, and less than ten, with two consecutive rising PSA values, checked at least 7 days apart. No PSA decline in last 42 day~3. Bone disease documented by either: a positive bone scan, CT scan, or MRI; or biopsy-proven bony metastases~4. Age ≥18 years~5. ECOG performance status ≤ 2 (Karnofsky ≥ 60%)~6. Have normal organ and marrow function defined as:~   * absolute neutrophil count ≥1,500/mcL~  * platelets ≥100,000/mcL~  * total bilirubin (within normal institutional limits)~  * AST/ALT ≤ 2.5 × ULN (or ≤ 1.5 x ULN in conjunction with alk phos \>2.5 x ULN for Docetaxel~  * AST ≤ 1.5 x ULN for Cabazitaxel~  * creatinine clearance-no minimum for Docetaxel~  * creatinine clearance- ≥ 30 mL/min/1.73 m2 for Cabazitaxel~7. No evidence of clinical progression, in the form of increased lesions on cross-sectional imaging, or new cancer-attributable symptoms or worsening of existing symptoms~8. Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~1. Patients who have residual toxicities \> Grade 2 attributed to taxane therapy, except for neuropathy, who are excluded if \> grade 1~2. Patients who are receiving any other investigational agents or have within the last 28 day.~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to clarithromycin or taxanes~4. Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible~5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~6. Received more than 10 cycles of docetaxel \[for docetaxel cohort only\] or 6 of cabazitaxel \[for cabazitaxel cohort only\]~7. Last docetaxel or cabazitaxel dose \> 6 weeks prior to enrollment~8. Patients with a documented history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes, or taking drugs that are known to prolong the QT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel and clarithromycin combination (Type: ACTIVE_COMPARATOR): Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.
- Cabazitaxel and clarithromycin combination (Type: ACTIVE_COMPARATOR): Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues